HER2 Positive and Triple Negative Breast Cancer: A Review
International Journal of Community Pharmacy · 30.09.2024 · 53-60
DOI: 10.65301/ijcp.2024.5.3.8 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Community Pharmacy, online erschienen am 30.09.2024. Verfasst von Viola Vinita DSA und 4 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background: Cancer is the most common cause of mortality and morbidity seen in all over the world. Breast cancer is the second most prevalent type of non-skin cancer and the fifth most common cause of cancer-related mortality worldwide, accounting for 10.4% of all cancer incidences among women. HER2 is a protein that plays a role in cell growth and differentiation accounts for 15-20% of HER2- Positive breast cancer. Lack of expression of Estrogen & Progesterone Receptor and the absence of human epidermal growth factor receptor 2 (HER2) and accounts for 15% of Triple negative breast cancer of all cases
Zitieren
APA
DSA, V. V., N, A. M., M, U., S, C. C., & Joshi, H. (2024). HER2 Positive and Triple Negative Breast Cancer: A Review. International Journal of Community Pharmacy, 53-60. https://doi.org/10.65301/ijcp.2024.5.3.8
Vancouver
DSA VV, N AM, M U, S CC, Joshi H. HER2 Positive and Triple Negative Breast Cancer: A Review. International Journal of Community Pharmacy. 2024:53-60. doi:10.65301/ijcp.2024.5.3.8
BibTeX
@article{DSA2024,
author = {DSA, Viola Vinita and N, Amith M and M, Umesh and S, Charan C and Joshi, Hanumanthachar},
title = {HER2 Positive and Triple Negative Breast Cancer: A Review},
journal = {International Journal of Community Pharmacy},
year = {2024},
pages = {53--60},
doi = {10.65301/ijcp.2024.5.3.8}
}
EUVIMED